Varicella Virus Vaccine
- Atc Codes:J07BK01
Table of contents
- Brand Names
- Drug Combinations
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Drug Interactions
- Dosage
- Special Considerations
Brand Names
Europe
Austria: Varilrix, Varivax; Belgium: Provarivax, Varilrix; Czech Republic: Varilrix; Estonia: Varilrix; Finland: Varilrix; France: Varilrix, Varivax; Germany: Varilrix, Varivax; Hungary: Varilrix; Ireland: Varivax; Italy: Varivax; Luxembourg: Varilrix; Netherlands: Varilrix; Poland: Varilrix; Portugal: Varilrix, Varivax; Spain: Varilrix, Varivax; Sweden: Varilrix; UK: Varilrix, Varivax.
North America
Canada: Varilrix, Varivax; USA: Varivax.
Latin America
Argentina: Varicela Biken, Varilrix; Brazil: Vacina Contra A Varicela; Mexico: Okavax, Varilrix.
Asia
Japan: Freeze-dried Live Attenuated Varicella Vaccine.
Drug combinations
Varicella Virus Vaccine and Neomycin
Chemistry
Pharmacologic Category
Serums, Toxoids, and Vaccines; Vaccines. Live Viral Vaccine. (ATC-Code: J07BK01).
Mechanism of action
Offers active immunity to disease caused by varicella-zoster virus.
Therapeutic use
Immunization against varicella in children ≥12 months of age and adults.
Pregnancy and lactiation implications
Contraindicated during pregnancy. Varicella disease during 1^st^ or 2^nd^ trimesters may result in congenital varicella syndrome. Use with caution in nursing women.
Unlabeled use
Contraindications
Hypersensitivity to any component of the vaccine. Individuals with blood dyscrasias, leukemia, lymphomas, or other malignant neoplasms affecting bone marrow or lymphatic systems. Those receiving immunosuppressive therapy. Primary and acquired immunodeficiency states. Family history of congenital or hereditary immunodeficiency. Active, untreated tuberculosis. Current febrile illness. Pregnancy.
Warnings and precautions
Anaphylactoid or hypersensitivity reactions might occur. May be administered to patients with mild acute illness (with or without low-grade fever). Vaccination may be considered for adolescents and adults with CD4^+^ T-lymphocyte counts ≥200 cells/μL. Varicella vaccine and antibody-containing products (e.g. immune globulin, blood products) should not be administered simultaneously. Salicylates should be avoided for 6 weeks after vaccination (varicella may increase risk of Reye’s syndrome). Products may contain albumin, gelatin, or neomycin. Vaccinated individuals should not have close association with susceptible high-risk individuals (newborns, pregnant women, immunocompromised persons) for 6 weeks following vaccination.